Publications
214
Citations
13,649
Est. group size
—
Recurring co-author estimate
Active years
27
Publishing since 2000
Ann Marie Hake conducts clinical research on brain disorders that affect memory and thinking, especially Alzheimer's disease and related dementias. Recent work focuses on digital health tools for tracking cognitive changes over time, and past studies include clinical trials of drug treatments for Alzheimer's disease and migraine. The research combines patient-based studies, biomarkers, and new measurement technologies.
Publication activity has been fairly steady but modest over the last decade, averaging about three papers per year in the most recent five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~11 · 0% small-team papers (≤3 authors) · across 24 venues
- Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia
Scientific Reports · 2026
- A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia
Frontiers in Digital Health · 2026
- Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge
Journal of Medical Internet Research · 2025
- Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort
The Journal of Prevention of Alzheimer s Disease · 2024
- Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis
The Lancet Neurology · 2024
- Digital Health Technologies for Alzheimer’s Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort
medRxiv · 2024
- Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge (Preprint)
2024
- Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia
Digital Biomarkers · 2023
- Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
Nature Communications · 2022
- The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
CNS Drugs · 2022
- Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease
Nature Communications · 2021
- Lasmiditan mechanism of action – review of a selective 5-HT1F agonist
The Journal of Headache and Pain · 2020
- FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease
Nature Communications · 2020
- Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
Neurology and Therapy · 2020
- The pathway to secondary prevention of Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions · 2020
- Scientific Reports×25
- Nature Communications×14
- Neurology×10
- GeroScience×8
- Alzheimer s & Dementia×7
- Judith L. Heidebrink
Medicine · University of Michigan
- Kun Ho Lee
Medicine · University of Michigan
- Donna M. Simpson
Medicine · Indiana University
- Anahita Adeli
Medicine · The Ohio State University
- Andrew J. Saykin
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile